AI Analysis

How does PER.AX make money? Does PER.AX have pricing power? What's the Earnings Whisper? Will PER.AX profit more as the business scales? What is PER.AX's management track record? Is PER.AX's current price justified?

Percheron Therapeutics Limited

AUD 0 -$0.00 (-55.56%)

ASX · 15 Sep 2026 23:59 UTC

Previous Close

AUD 0

Day Range

AUD 0AUD 0

Year Range

AUD 0AUD 0.01

Market Cap

4.46M

AVG Volume

3.65M

Trailing/Forward PE

-0.98/-

PEG ratio

-0

Dividend Yield

Next Earnings Date

2027-02-24

Primary Exchange

Australian Securities Exchange

Free Cash Flow Yield

PER.AX Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-481.14%
Sep 26	-481.14%
Sep 26	-433.03%
Aug 26	-433.03%
Aug 26	-433.03%
Aug 26	-433.03%
Aug 26	-721.71%
Jul 26	-721.71%
Jul 26	-721.71%
Jul 26	-721.71%
Jul 26	-721.71%
Jul 26	-618.61%
Jun 26	-541.29%
Jun 26	-433.03%
Jun 26	-541.29%
Jun 26	-433.03%
May 26	-541.29%
May 26	-541.29%
May 26	-541.29%
May 26	-541.29%
May 26	-433.03%
Apr 26	-433.03%
Apr 26	-541.29%
Apr 26	-433.03%
Apr 26	-433.03%
Mar 26	-419.39%
Mar 26	-457.52%
Mar 26	-503.27%
Mar 26	-369.08%
Feb 26	-369.08%
Feb 26	-359.48%
Feb 26	-314.55%
Feb 26	-314.55%
Jan 26	-279.6%
Jan 26	-314.55%
Jan 26	-314.55%
Jan 26	-279.6%
Jan 26	-279.6%
Dec 25	-314.55%
Dec 25	-314.55%
Dec 25	-251.64%
Dec 25	-359.48%
Nov 25	-359.48%
Nov 25	-314.55%
Nov 25	-359.48%
Nov 25	-359.48%
Oct 25	-314.55%
Oct 25	-314.55%
Oct 25	-279.6%
Oct 25	-251.64%
Oct 25	-228.76%

Price to Book

PER.AX Price to Book by year
Period	Price to Book
Sep 26	0.69
Sep 26	0.69
Sep 26	0.76
Aug 26	0.76
Aug 26	0.76
Aug 26	0.76
Aug 26	0.46
Jul 26	0.46
Jul 26	0.46
Jul 26	0.46
Jul 26	0.46
Jul 26	0.53
Jun 26	0.61
Jun 26	0.76
Jun 26	0.61
Jun 26	0.76
May 26	0.61
May 26	0.61
May 26	0.61
May 26	0.61
May 26	0.76
Apr 26	0.76
Apr 26	0.61
Apr 26	0.76
Apr 26	0.76
Mar 26	0.61
Mar 26	0.56
Mar 26	0.51
Mar 26	0.7
Feb 26	0.7
Feb 26	0.72
Feb 26	0.82
Feb 26	0.82
Jan 26	0.92
Jan 26	0.82
Jan 26	0.82
Jan 26	0.92
Jan 26	0.92
Dec 25	0.82
Dec 25	0.82
Dec 25	1.02
Dec 25	0.72
Nov 25	0.72
Nov 25	0.82
Nov 25	0.72
Nov 25	0.72
Oct 25	0.82
Oct 25	0.82
Oct 25	0.92
Oct 25	1.02
Oct 25	1.13
Sep 25	0.61
Sep 25	0.61
Sep 25	0.55
Sep 25	0.55
Aug 25	0.67
Aug 25	0.61
Aug 25	0.58
Aug 25	0.67
Aug 25	0.55
Jul 25	0.55
Jul 25	0.49
Jul 25	0.55
Jul 25	0.49
Jun 25	0.55
Jun 25	0.61
Jun 25	0.61
Jun 25	0.61
May 25	0.67
May 25	0.61
May 25	0.61
May 25	0.61
May 25	0.55
Apr 25	0.61
Apr 25	0.73
Apr 25	0.61
Apr 25	0.67
Mar 25	0.67
Mar 25	1.06
Mar 25	1.06
Mar 25	1.06
Mar 25	0.87
Feb 25	1.25
Feb 25	0.67
Feb 25	0.67
Jan 25	0.77
Jan 25	0.87
Jan 25	0.87
Jan 25	0.87
Jan 25	0.87
Dec 24	0.77
Dec 24	0.67
Dec 24	5.68
Dec 24	6.74
Nov 24	7.13
Nov 24	7.13
Nov 24	7.61
Nov 24	7.7
Nov 24	7.61
Oct 24	7.8

No video analysis for this stock yet. Request one from our team.

News: PER.AX

feeds.newsfilecorp.com · 4 Sep 2026

Edison Issues Report on Percheron Therapeutics (PER)

London, United Kingdom--(Newsfile Corp. - September 4, 2026) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron's clinical strategy has

proactiveinvestors.com · 31 Aug 2026

Percheron Therapeutics receives $700,000 R&D rebate to support HMBD-002 cancer program

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has received a $700,000 Research and Development Tax Incentive rebate for the 2026 financial year, providing...

proactiveinvestors.com · 5 Aug 2026

Percheron Therapeutics Phase II progress highlighted by Edison with 5.5-cent valuation

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) (Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF)) remains on track to begin a Phase II trial of HMBD-002 in...